Clinical trial · Interventional
Effect of Enhanced Recovery After Surgery (ERAS) on C-reactive and Visceral Proteins
Effect of Enhanced Recovery After Surgery (ERAS) on C-reactive and Visceral Proteins in Patients With Advanced Gastric Cancer
NCT02348229CI-TRIAL-00016724ERASAGcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators designed a prospective randomized, controlled clinical trial then recruited 149 consecutive advanced gastric cancer patients. Further divided into a ERAS group (n=73) and a conventional pathway group (n=76). Surgical technique in both groups was same laparoscopic-assisted gastrectomy with D2 lymphadenectomy. Compared outcomes included clinical parameters and serum indicators.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional pathway group | Procedure | — | UNRESOLVED |
| ERAS protocols | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ERAS group
- description
- ERAS protocols
- interventionNames
- Procedure: ERAS protocols
- type
- OTHER
- label
- conventional pathway group
- description
- using conventional pathway
- interventionNames
- Procedure: conventional pathway group
Primary outcomes (1)
- measure
- Compartition of postoperative hospital stay
- timeFrame
- up to 30 days after the operation
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18-75 years old 2. Diagnosis confirmed by the endoscopic biopsy and total-body CT scan 3. No history of the chronic renal disease ,chronic liver disease, cardiopulmonary dysfunction, ASA score≦3 4. No neoadjuvant chemotherapy and radiotherapy 5. No digestive obstruction and distant metastasis Exclusion Criteria: 1. Conversion to open gastrectomy 2. A large amount of bleeding leading(\>500ml) 3. Patients withdrew their consent
References
Publications (1)
- DERIVEDMingjie X, Luyao Z, Ze T, YinQuan Z, Quan W. Laparoscopic Radical Gastrectomy for Resectable Advanced Gastric Cancer Within Enhanced Recovery Programs: A Prospective Randomized Controlled Trial. J Laparoendosc Adv Surg Tech A. 2017 Sep;27(9):959-964. doi: 10.1089/lap.2016.0057. Epub 2016 Nov 22. PMID 27875094